Jazz Releases Full Survival Data for Zepzelca in Lung Cancer at ASCO 2025

Jazz Pharmaceuticals presented full survival data for its lung cancer drug Zepzelca (lurbinectedin) in combination with Roche's Tecentriq (atezolizumab) at ASCO 2025, based on the Phase 3 IMforte trial results.12345

The combination therapy reduced the risk of death by 27% versus Tecentriq alone as first-line maintenance for extensive-stage small cell lung cancer (ES-SCLC).23

Median overall survival was 13.2 months for the Zepzelca + Tecentriq group, compared to 10.6 months for Tecentriq alone.3

The combination also resulted in a 46% lower risk of cancer progression or death, with progression-free survival of 5.4 months (combo) vs. 2.1 months (Tecentriq alone).3

The data are regarded as statistically significant and clinically meaningful, supporting the potential for Zepzelca to move from post-chemo to first-line ES-SCLC treatment.45

Jazz Pharmaceuticals has submitted an application to the FDA for full approval of Zepzelca in this new setting following the positive Phase 3 results.2

Sources:

1. https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-showcases-transformative-data-asco-2025

2. https://endpts.com/asco25-jazz-outlines-full-survival-data-for-lung-cancer-drug-zepzelca/

3. https://www.fiercepharma.com/pharma/asco-roche-jazz-zepzelca-small-cell-lung-cancer-win-leaves-room-improvement

4. https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-showcases-transformative-data-at-asco-2025-highlighting-advances-in-small-cell-lung-cancer-her2-gastroesophageal-cancer-and-diffuse-glioma-302436392.html

5. https://www.appliedclinicaltrialsonline.com/view/zepzelca-tecentriq-survival-extensive-stage-small-cell-lung-cancer